Hcv clinical trials

Explore recruiting hcv clinical trials.

Recruiting hcv studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hcv trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Vaccination to prevent Mpox Infection (MPOX-VAX Study)

Ireland

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis

Germany, Poland, Austria, Italy, Czechia, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Romania, France, Germany, Greece, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients with PD-L1 combined positive score (CPS)≥1≤19: the immunotherapy.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis

Spain, Germany, Czechia, Poland, Greece, Austria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Impact of dextroamphetamine substitution on the use of illicit amphetamines in adults with comorbid dependencies to amphetamines and opioids undergoing opioid agonist treatment: A multi-center double blind randomized controlled study (ATLAS4Dependence)

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Hcv trials by city

Hcv in Toronto Hcv in Vancouver Hcv in Montreal Hcv in Calgary Hcv in Edmonton Hcv in Ottawa Hcv in Winnipeg Hcv in Quebec City Hcv in Hamilton Hcv in Kitchener Hcv in London Hcv in Halifax Hcv in New York Hcv in Los Angeles Hcv in Chicago Hcv in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease